# Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.

> **NCT07394387** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 58 (estimated)

## Conditions studied

- Triple Negative Breast Cancer (TNBC)

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** Abraxane
- **DRUG:** Carboplatin
- **PROCEDURE:** High-intensity focused ultrasound (HIFU)

## Key facts

- **NCT ID:** NCT07394387
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-01
- **Primary completion:** 2026-06
- **Final completion:** 2026-12-31
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07394387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07394387, "Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT07394387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*